MZL,   FL,  CLL/SLL,  DLBCL

Jean-Marie Michot | EHA 2018 | What are the key safety and efficacy outcomes of the CC-122 and obinutuzumab study in R/R B-cell NHL?

L: English
Watch French version

23rd Congress of European Hematology Association, 14-17 June 2018, Stockholm, Sweden

Jean-Marie Michot
Gustave Roussy Institute of Cancer, Villejuif, FR

Interview topic: What are the key safety and efficacy outcomes of the CC-122 and obinutuzumab study in R/R B-cell NHL?

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF